The company told News18 that the robust research and clinical trials have consistently established the safety and efficacy of ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

Nomura recommends Buy for Dr. Reddy’s, Cipla, Lupin, Zydus amid pharma stock pressure. Check latest market trends!

A recent CDC study said greater access to fertility treatments and more education for teens have led to a role reversal in ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used ...

Nimesulide, a widely used painkiller in India, is facing renewed regulatory scrutiny over its safety profile, with India's ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

HYDERABAD: Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian arm, Sanofi Healthcare India Pvt Ltd (SHIPL), to bring a ...

At the India Health Summit 2025, experts discussed making healthcare affordable by integrating digital tools, skilled ...